| Certificates/Standards: | N; |
| Monthly Output: | 500t/Year |
| Regional: | China |
| Packaging Information: | 25kg/Drum |
| Mode Of Payment: | Not provided |
| Delivery Lead Time: | Not provided |
| Main Sales Markets: | North America，Central/South America，Western Europe，Eastern Europe，Australasia，Asia，Middle East，Africa |
| Sample Provided: | No |
| Sample Policy: | Not provided |
| Minimum Quantity: | Not provided |
1. Vitamin K2(20) (MK-4) Menquinon-4 [CAS No.: 863-61-6]
2. Vitamin K2(35) (MK-7) Menquinon-7 [CAS No.: 27670-94-6]
3. Vitamin K2(45) (MK-9) Menquinon-9 [CAS No.: 523-39-7]
Function of Vitamin K2:
1. Curing and preventing osteoporosis
2. Curing haemorrhage caused by VK2 deficiency
3. Function of diuresis, promoting the detoxifcation of liver and lowering blood pressure.
4. VK2 is a PKA active regulator used for preventing and treating hepatic disease. And it can be used for treating liver cancer and lung cancer.
We Shanghai Seebio Biotechnology Inc. Are the only manufacturer of Vitamin K2 in China. Welcome to contact us for more.
Functions of Vitamin K2
1. Curing and preventing osteoporosis: VK2 produces a specific protein known as osteocalcin which can bind calcium, therefore to increase the density of bones and to prevent fracture.
2. Curing haemorrhage caused by VK2 deficiency: It promotes the formation of thrombin, accelerates blood clotting, maintains proper clotting time; and also used as quick coagulant in surgeries or first aids.
3. Function of diuresis, promoting the detoxifcation of liver and lowering blood pressure.
4. VK2 is a PKA active regulator used for preventing and treating hepatic disease. And it can be used for treating liver cancer and lung cancer.
Vitamin K2's effects on osteoporosis
Vitamin K2 is a cofactor of gamma-carboxylase, which converts the glutamic acid (Glu) residue in steocalcin molecules to gamma-carboxyglutamic acid (Gla), and is, therefore, essential for gamma-carboxylation of osteocalcin. Vitamin K2 also enhances osteocalcin accumulation in the extracellular matrix of osteoblasts in vitro. Osteocalcin-knockout mice develop hyperostosis, suggesting that the Gla-containing osteocalcin promotes normal bone mineralization, and it probably regulates the growth of hydroxyapatite crystals. Vitamin K2 also inhibits the expression of the osteoclast differentiation factor (ODF)/RANK ligand, tartrate-resistant acid phosphatase activity, and mononuclear cell formation, and induces osteoclast apoptosis in vitro.
Furthermore, bone pectin is formed by osteocalcin produced with vitamin K2 and protein, and calcium, then caccumulates in bone. So vitamin K2, calcium and protein are three factors which are essential to increase bone density. There is some evidence indicating that vitamin K2 prevents bone resorption in ovariectomized rats, retards the increase in bone turnover in orchidectomized rats, ameliorates the increase in bone resorption and decrease in bone formation in sciatic neurectomized rats, and prevents the decrease in bone formation in glucocorticoid-treated rats. These findings suggest that vitamin K2 may not only stimulate bone formation but also suppress bone resorption in vivo. Clinically, vitamin K2 sustains the lumbar bone mineral density (BMD) and prevents osteoporotic fractures in patients with age-related osteoporosis, prevents vertebral fractures in patients with glucocorticoid-induced osteoporosis, increases the metacarpal BMD in the paralytic upper extremities of patients with cerebrovascular disease, and sustains the lumbar BMD in patients with liver-dysfunction-induced osteoporosis.
Forms
Vitamin K2(20) (MK-4) Menaquinon-4 Capsules and Tablets
Vitamin K2(35) (MK-7) Menaquinon-7 Capsules and Tablets
Vitamin K2(45) (MK-9) Menaquinon-9 Capsules and Tablets
1. Vitamin K2(20) (MK-4) Menaquinon-4
Product Code: 185834
Code
Specification
MOQ
DCF0004A (1858344)
0.25% Oil
100 Kg
DCF0004B (1858343)
0.5% Powder (sustained release preparation)
25 Kg
DCF0004C (1858342)
1.3% Oil
25 Kg
DCF0004D (1858341)
1.3% Powder (sustained release preparation)
10 Kg
DCF0004E (1858345)
98.0% Powder (Equivalent to JP15)
1 Kg
DCF0004F (1858340)
98.0% Oil (JP15)
1 Kg
Alternative Names: Vitamin K2, menaquinone, menaquinon-4, menatetrenone, menatetren, menatetrenona, menatetrenonum, MK-4, E3100; 2-methyl-3-[(2'E,6'E,10'E)-3',7',11',15'- tetramethylhexadeca-2',6',10',14'- tetraen-1'-yl]-1,4-naphthalenedione
CAS Code: [863-61-6] or [11032-49-8]
Molecular Formula: C31H40O2
Molecular Weight: 444.65
Shelf life: 2 years
Hazard Class: Non-hazardous
2. Vitamin K2(35) (MK-7) Menaquinon-7
Product Code: 185837
Code
Specification
MOQ
ACF0003T (18583751)
1.0% on DCP or CD (Pharm. excipient CaHPO4)
25 Kg
ACF0003V (18583755)
0.5% on DCP or CD (Pharm. excipient CaHPO4)
25 Kg
ACF0003A (1858374)
1.0% Oil
25 Kg
ACF0003B (1858373)
0.5% Powder (sustained release preparation)
25 Kg
ACF0003C (1858372)
1.3% Oil
1-5 Kg
ACF0003D (1858371)
1.3% Powder (sustained release preparation)
1 Kg
Alternative Names: Menaquinon-7; MK-7; (all-E)-2-(3,7,11,15,19,23,27-Heptamethyl -2,6,10,14,18,22,26-octacosaheptaenyl)-3-methyl-1,4-naphthalenedione ;
CAS Code: [27670-94-6]
Molecular Formula: C46H64O2
Molecular Weight: 649.0
Shelf life: 2 years
Hazard Class: Safe
3. Vitamin K2(45)(MK-9) Menaquinon-9
Product Code: 185838
Code
Specification
MOQ
DCF0005A (185838)
98% Powder
1 Kg
Alternative Names: Menaquinon-9; MK-9 ; (all-E)-2-(3,7,11,15,19,23,27,31,35-Heptamethyl- 2,6,10,14,18,22,26,30,34-octacosaheptaenyl)-3-methyl-1,4-naphthalenedione ;
CAS Code: [523-39-7]
Molecular Formula: C56H80O2
Molecular Weight: 784.0
Shelf life: 2 years
Hazard Class: Non-hazardous
沪公网安备31010402001403号
